Clinical trial

Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA)…

NCT00353288 · GlaxoSmithKline, Industry · Completed

Key facts

NCT number NCT00353288
Title Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
Official title Comparative Study Evaluating the Immunogenicity and Safety of MeMuRu-OKA Vaccine and Measles-mumps-rubella Vaccine (Priorix™) Co-administered With Varicella Vaccine (Varilrix™) in Children Primed With Measles-mumps-rubella Vaccine
Lead sponsor GlaxoSmithKline, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Varicella, Rubella, Measles, Mumps
Intervention type Biological
Interventions MeMuRu-OKA (study vacc), MMR, Varicella vacc (control)
Enrollment 446
Start date Mar 1, 2006
Primary completion Nov 1, 2006
Completion Nov 1, 2006
First posted Jul 18, 2006
Last update posted Oct 7, 2016
Countries France, Germany, Italy

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies